Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors (NCT07030257)
A Multi-Center, Open Label, Phase 1/2 Study of CP-383, in Patients With Advanced or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383 Participants will: * Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth * Visit the clinic weekly for the first 6 weeks for checkups and tests * Visit the clinic every 3 weeks thereafter for checkups and tests
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute at HealthONE — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Florida Cancer Specialists-Lake Nona — Orlando, Florida
- START Midwest — Grand Rapids, Michigan
- Washington University — St Louis, Missouri
- Nebraska Cancer Specialists — Omaha, Nebraska
- Carolina BioOncology Institute — Huntersville, North Carolina
- Cleveland Clinic — Cleveland, Ohio
- Taylor Cancer Research Center — Maumee, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- NEXT Oncology - Dallas — Dallas, Texas
- START San Antonio — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
- NEXT Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (617) 430-7109
Email: trials@tascatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor Malignancies
- Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study — Toronto, Ontario
- Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) — Tucson, Arizona
- A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies — La Jolla, California
- Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors — Scottsdale, Arizona
- A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases — Detroit, Michigan
Explore by condition: All Solid Tumor Malignancies clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.